Piramal Pharma Limited · NSE:PPLPHARMA
Piramal Pharma — Q4 FY2023 Earnings Presentation
34 slides from Piramal Pharma's earnings presentation, May 25, 2023
Slide 1: Exchange filing cover letter
24th May, 2023 BSE Limited National Stock Exchange of India Limited P.J. Towers, Dalal Street, Fort, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (East), Mumbai – 400 051 BSE scrip code: 543635 NSE symbol: PPLPHARMA Sub: Press Release and Investor Presentation – Audited Financial Res
Slide 2: Piramal Pharma Limited Announces Consolidated Results for Q4 and FY2023
PRESS RELEASE Piramal Pharma Limited Announces Consolidated Results for Q4 and FY2023 Mumbai, India | May 24, 2023: Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), today announced its consolidated results for the fourth quarter (Q4) and full year FY23 ended 31st March 2023. Consolidated Finan
Slide 3: Key Business Highlights for Q4 and FY23
Key Business Highlights for Q4 and FY23 Contract Development and Manufacturing Organization (CDMO): - Witnessed a significant pickup in order bookings in Q4 compared to the previous three quarters. The orders received during Q4 was a healthy mix of on-patent and generic product development and manuf
Slide 4: Consolidated Profit and Loss Statement
Consolidated Profit and Loss Statement (In INR Crores) Reported Financials Quarter Full Year Particulars YoY QoQ YoY Q4 FY23 Q4 FY22 Q3 FY23 FY23 FY22 Change Change Change Revenue from Operations 2,164 2,131 2% 1,716 26% 7,082 6,559 8% Other Income 25 78 -69% 83 -70% 225 276 -18% Total Income 2,188
Slide 5: Like-to-Like Financials
Forwarding Agent) network till all requisite licenses, registrations, permits were fully transferred in the name of PPL. In accordance with the scheme the demerger of pharma undertaking has been considered as non-common control transaction and accounted as business combination as per Ind-AS 103 in t
Slide 6: Consolidated Balance Sheet
Consolidated Balance Sheet (In INR Crores) As at Key Balance Sheet Items 31-Mar-23 31-Mar-22 Total Equity 6,773 6,697 Net Debt 4,781 3,656 Deferred Consideration 11 90 Total 11,565 10,443 Net Fixed Assets 8,887 8,051 Tangible Assets 4,441 3,716 Intangible Assets including goodwill 4,446 4,336 Net Wo
Slide 7: Q4 and FY2023 Earnings Conference Call
Q4 and FY2023 Earnings Conference Call Piramal Pharma Limited will be hosting a conference call for investors / analysts on 25th May 2023 at 5:00 PM (IST) to discuss its Q4 and FY2023 Results. The dial-in details for the call are as under: Event Location & Time Telephone Number +91 22 6280 1461 / +9
Slide 8: Piramal Pharma Limited Q4 & FY2023 Results Presentation
Piramal Pharma Limited – Q4 and FY2023 Results Presentation Piramal Pharma Limited Q4 & FY2023 Results May 2023
Slide 9: Disclaimer
Piramal Pharma Limited – Q4 and FY2023 Results Presentation Page 2 Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Piramal Pharma Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, re
Slide 10: Key Highlights of the Financial Year
Piramal Pharma Limited – Q4 and FY2023 Results Presentation Page 3 Key Highlights of the Financial Year Key Financial Highlights Revenue grew by 8% YoY in FY23 Diversified Revenue Mix (In INR Crore) Revenue EBITDA Margin Others ICH 11% CDMO 19% 12% 12% 57% North America 45% India 20% FY23 FY23 7,082
Slide 11: Key Highlights of the Financial Year
Piramal Pharma Limited – Q4 and FY2023 Results Presentation Page 4 Key Highlights of the Financial Year Strategic Initiatives Best-in-Class Quality Track Record Integrating Sustainability 36 Successful regulatory inspections in FY23 . . 4 Successful US FDA inspections in FY23 Zero OAIs#* Establish
Slide 12: Details on the Rights Issue
Piramal Pharma Limited – Q4 and FY2023 Results Presentation Page 5 Details on the Rights Issue Progress on the Rights Issue not exceeding INR 1,050 Cr. February 2023 - The Board of Directors of the Company approved the recommendation to allot equity shares for an amount not exceeding INR 1,050 Cr.
Slide 13: Key Highlights of the Quarter (Q4FY23)
Piramal Pharma Limited – Q4 and FY2023 Results Presentation Page 6 Key Highlights of the Quarter (Q4FY23) Key Highlights Revenue and EBITDA performance* (In INR Crore) Revenue EBITDA Margin Revenue from Operations in Q4FY23 was Rs.2,164Cr – growth of 26% QoQ and 2% YoY • EBITDA margin in Q4FY23 wa
Slide 14: CDMO Business (Piramal Pharma Solutions)
Piramal Pharma Limited – Q4 and FY2023 Results Presentation Page 7 CDMO Business (Piramal Pharma Solutions)
Slide 15: Contract Development and Manufacturing Organization Business
Piramal Pharma Limited – Q4 and FY2023 Results Presentation Page 8 Contract Development and Manufacturing Organization Business Performance Highlights Revenue performance* in Q4FY23 (In INR Crore) Pick-up in order inflows: • Witnessed significant pick-up in order bookings in Q4FY23 compared to pre
Slide 16: Presence across Value Chain – Discovery, Development, Commercial Manufacturing
Piramal Pharma Limited – Q4 and FY2023 Results Presentation Page 9 Presence across Value Chain – Discovery, Development, Commercial Manufacturing High proportion of Commercial and Phase III development revenue FY23 Revenue by Services Pre-clinical 20% Phase III 5% 43% 30% FY23 Strong Growth in Comme
Slide 17: Attracting Customers with our Differentiated Offerings and Integrated Services
Piramal Pharma Limited – Q4 and FY2023 Results Presentation Page 10 Attracting Customers with our Differentiated Offerings and Integrated Services Differentiated Offerings Integrated Projects 200+ Potent sterile Integrated projects executed till date Peptide injectables 32 number of integrated proje
Slide 18: Growth Drivers for CDMO Business
Piramal Pharma Limited – Q4 and FY2023 Results Presentation Page 11 Growth Drivers for CDMO Business Near-term Visible Revenue Growth Levers Upsides Beyond the Plan Pursue inorganic growth Customer Focus on expanding Capability technical/product capabilities Support progression of existing and t
Slide 19: Complex Hospital Generics (Piramal Critical Care)
Piramal Pharma Limited – Q4 and FY2023 Results Presentation Page 12 Complex Hospital Generics (Piramal Critical Care)
Slide 20: Complex Hospital Generics Business
Piramal Pharma Limited – Q4 and FY2023 Results Presentation Page 13 Complex Hospital Generics Business Performance Highlights Revenue growth* in Q4 FY23 (In INR Crore) Continued momentum in Inhalation Anesthesia (IA) sales in the US with volume 702 growth driving market share gains • Leading playe
Slide 21: Differentiated Portfolio for Gaining Market Share and Driving Growth
Piramal Pharma Limited – Q4 and FY2023 Results Presentation Page 14 Differentiated Portfolio for Gaining Market Share and Driving Growth Vertically Integrated Manufacturing Capabilities with Global Differentiated portfolio spanning inhalation anesthesia and injectable Regulatory Accreditations Inhal
Slide 22: Flexible Blend of Direct Commercialization Capabilities and Local Partners
Piramal Pharma Limited – Q4 and FY2023 Results Presentation Page 15 Flexible Blend of Direct Commercialization Capabilities and Local Partners Marketing worldwide through a global sales and distribution network Established channel relationships and robust commercial infrastructure Direct sales f
Slide 23: Growth Drivers for CHG Business
Piramal Pharma Limited – Q4 and FY2023 Results Presentation Page 16 Growth Drivers for CHG Business Near-term Visible Revenue Growth Levers Upsides Beyond the Plan Business acquisitions Vertical Differentiated integration portfolio Carrying out synergistic Strong pipeline product and business Co
Slide 24: India Consumer Healthcare (Consumer Products Division)
Piramal Pharma Limited – Q4 and FY2023 Results Presentation Page 17 India Consumer Healthcare (Consumer Products Division)
Slide 25: India Consumer Healthcare Business
Piramal Pharma Limited – Q4 and FY2023 Results Presentation Page 18 India Consumer Healthcare Business Performance Highlights Revenue growth* in Q4 FY23 (In INR Crore) New Product launches - 26 new products and 37 new SKUs launched in FY23. NPDs launched since Apr’20 contribute to 18% of sales 206
Slide 26: Focus on Power Brands with Continuous Investments in Brand Promotion and Marketing
Piramal Pharma Limited – Q4 and FY2023 Results Presentation Page 19 Focus on Power Brands with Continuous Investments in Brand Promotion and Marketing Investments in brand promotion and marketing Kareena Kapoor Priyanka Mohan Sourav Ganguly Amyra Dastur Ajay Devgan i-pill Daily Little’s Lacto - Sout
Slide 27: Diversified Portfolio of Attractive Brands, Including Power Brands
Piramal Pharma Limited – Q4 and FY2023 Results Presentation Page 20 Diversified Portfolio of Attractive Brands, Including Power Brands Analgesics Skin care VMS Women’s health Digestives Kids wellness Health & Hygiene Lacto Calamine i-pill, i-know Saridon® Supradyn® Littles Oil Control Lotion, Contra
Slide 28: Well Established Commercial Infrastructure with Multi-channel Distribution Strategy
Piramal Pharma Limited – Q4 and FY2023 Results Presentation Page 21 Well Established Commercial Infrastructure with Multi-channel Distribution Strategy Wide coverage across general trade, chemist and toy shops Strengthening presence across alternate channels Revenue share of 10% 20% alternate channe
Slide 29: Financials
Piramal Pharma Limited – Q4 and FY2023 Results Presentation Page 22 Financials
Slide 30: Explanation on Financial Statement
Piramal Pharma Limited – Q4 and FY2023 Results Presentation Page 23 Explanation on Financial Statement Note explaining why Q4FY23 and FY23 financials are strictly not comparable to Q4FY22 and FY22 The scheme of demerger of the pharma business (PPL) from the PEL and amalgamation of PPL’s wholly owned
Slide 31: Consolidated Financials Highlights – Profit & Loss Statement
Piramal Pharma Limited – Q4 and FY2023 Results Presentation Page 24 Consolidated Financials Highlights – Profit & Loss Statement (In INR Crores or as stated) Reported Financials Like-to-Like Financials Particulars Q4FY23 Q3FY23 QoQ Change Q4FY22 YoY Change Q4FY23 Q3FY23 QoQ Change Q4FY22 YoY Change
Slide 32: Consolidated Financials Highlights – Balance Sheet
Piramal Pharma Limited – Q4 and FY2023 Results Presentation Page 25 Consolidated Financials Highlights – Balance Sheet (In INR Crores) Key Balance Sheet Items 31-Mar-23 31-Mar-22 Total Equity 6,773 6,697 Net Debt 4,781 3,656 Deferred Consideration 11 90 Total 11,565 10,443 Net Fixed Assets 8,887 8,0
Slide 33: Dial-in details for Q4 and FY2023 Earnings Conference Call
Piramal Pharma Limited – Q4 and FY2023 Results Presentation Page 26 Dial-in details for Q4 and FY2023 Earnings Conference Call Event Location & Time Telephone Number +91 22 6280 1461 / +91 22 7115 8320 (Primary Number) India – 5:00 PM IST 1 800 120 1221 (Toll free number) USA – 7:30 AM Toll free num
Slide 34: For Investor Queries
Piramal Pharma Limited – Q4 and FY2023 Results Presentation Page 27 For Investor Queries: Gagan Borana General Manager – Investor Relations & Sustainability Email : gagan.borana@piramal.com Phone : +91 22 3802 3090